Recent

% | $
Quotes you view appear here for quick access.

Delek US Holdings, Inc. Message Board

TwoJugglers 326 posts  |  Last Activity: 1 hour 11 minutes ago Member since: Apr 6, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Shorts about to lose their shirts!!!

    by cashmoo2 23 hours ago
    twojugglers twojugglers 1 hour 11 minutes ago Flag

    Wow, nice to see some new posters here.

    Sentiment: Strong Buy

  • Reply to

    Organovo Christmas Party!!

    by cashmoo2 17 hours ago
    twojugglers twojugglers 10 hours ago Flag

    Cool find Moo!

    Sentiment: Strong Buy

  • twojugglers twojugglers 10 hours ago Flag

    jj5460md,

    Well said, and entirely on point.

    Thanks,

    Juggsy

    Sentiment: Strong Buy

  • At genengnews (Genetic Eng. and BioTech News)

    The era of three-dimensional (3D) printing has arrived—not just the 3D printing of uniform solids, but the 3D printing of heterogeneous, living tissues. If you are content with producing inert objects, you can use the 3D printers sold at Barnes & Noble.

    But if you want to construct human tissue, you will need a bioprinter, a device that can lay down living cells in patterns that are correct in exacting detail. Fortunately, bioprinters are becoming commonplace, and the applications that they enable—such as 3D cell cultures—are starting to go mainstream.

    The global market for 3D cell cultures is poised for explosive growth. According to BCC Research, it will reach $2.2 billion by 2019. This growth, which is supported by an unprecedented pace of innovation, is a response to the increased demand for safety testing in drug discovery.

    Advances in 3D cellular design were showcased at the recent 3D Models and Drug Screening Conference, which was organized by the Global Technology Community. The event, which was held in Berlin, highlighted the use of bioprinters to construct human liver tissue; the genetic manipulation of stem cells to create mini-brains, and the development of tools and imaging technologies for high-content phenotypic screening and validation. Applications discussed at the meeting ranged from drug design to safety testing, and from cancer therapeutics to regenerative medicine.

    A tissue engineer at Organovo loads bioink into one of the company’s bioprinters. The procedure is part of a process to generate functional 3D human tissue models for preclinical testing and drug discovery research. One such model is Organovo’s exVive3D Human Liver Tissue.
    For many years, scientists have struggled to capture the form and replicate the function of native tissues. Although native tissues possess subtleties that still elude 3D culture systems, scientists are making progress. For example, scientists at Organovo hav

    Sentiment: Strong Buy

  • twojugglers twojugglers 21 hours ago Flag

    From Business Insider, Australia:

    You don’t want to think about how your favourite leather jacket, shoes or watch strap were made.

    But the process — from the time it takes to farm an animal, ship it to a slaughter facility, prepare and then tan the hide — can take years.

    In Brooklyn, a team of 35 people have found a way to create real leather in about two weeks. And their process doesn’t harm any animals.

    Modern Meadow says no animals are harmed to grow its leather. Instead it just uses some skin cells.
    Modern Meadow is a startup that has over a dozen patents and grows leather in a lab from skin cells that produce collagen, a protein found in the connective tissues of animals. That collagen turns into leather that’s free of blemishes, hair and fat.

    For the past four years, Modern Meadow has been focused on research and development. Now, it’s raised $40 million from Nest founder Tony Fadell, Li Ka-shing’s Horizon Ventures, the “Zuck and friends’ billionaire fund” Iconiq Capital, Breakout Capital, Artis Ventures, and Singapore’s Temasek to bring its material to the masses.

    “We are making real, fully biological leather here,” Modern Meadow co-founder and CEO Andras Forgacs told Tech Insider. That’s unlike most synthetic leather which is made from plastic and chemicals.

    “[Making leather] is this really long process with a lot of inefficiencies,” Forgacs said. “You’re working subtractively, removing the hair, flesh and the fat [from the hide] … Instead we work additively. We just create collagen to make the material and that’s it.”

    Sentiment: Strong Buy

  • A Brooklyn-based startup called Modern Meadow has raised $40 million to become a top source of leather for the world’s makers of fashion and accessories, luggage, sporting goods, upholstery and furniture.

    Rather than raising animals to slaughter them and take the skin off their backs in a physically and chemically intensive process, Modern Meadow “biofabricates” its leather in labs and foundries.

    Modern Meadow CEO and co-founder Andras Forgacs explains that biofabrication involves the design of cells to produce and assemble collagen and other proteins to yield leather that is “biologically identical” to traditional types.

    Biofabrication is environmentally beneficial, he believes. He said, “We’re making a material that has no hair flesh or fat on it. So the liming and toxicity you see elsewhere in the leather trade is eliminated.”

    Chief Creative Officer for Modern Meadow, Suzanne Lee, said the company’s processes can generate leather that’s made to a designer’s specifications and imbued with desirable traits like a certain flexibility, elasticity, thinness or thickness.

    Once produced, the leathers can go to a tannery for additional dyeing, she noted.

    Horizons Ventures, an equity investing vehicle for Li Ka-shing, and Iconiq Capital led Modern Meadow’s Series B round, joined by ARTIS Ventures, Temasek, Breakout Ventures, Red Swan Ventures, Collaborative Fund and Tony Faddell, the inventor, designer and founder of Nest Labs.

    The funding brings Modern Meadow’s total capital raised to $53.5 million to-date.

    Sentiment: Strong Buy

  • "Organovo Holdings Inc. (ONVO) was among the biggest gainers on the Russell 2000 for Tuesday June 28 as the stock popped 8.39% to $3.36, representing a gain of $0.26 per share. Some 1.21 million shares traded hands on 3,108 trades, compared with an average daily volume of 638,219 shares out of a total float of 92.39 million. The stock opened at $3.25 and traded with an intraday range of $3.44 to $3.17.

    After today's gains, Organovo Holdings Inc. reached a market cap of $310.44 million. Organovo Holdings Inc. has had a trading range between $4.13 and $1.60 over the last year, and it had a 50-day SMA of $2.84 and a 200-day SMA of $2.69.

    Organovo Holdings Inc is a development-stage company. It is engaged in developing and commercializing functional human tissues."

    Sentiment: Strong Buy

  • twojugglers twojugglers 23 hours ago Flag

    You are exactly right!!!

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 4:20 PM Flag

    Which reminds me OnvoBaby,

    Do you know what the last this is that goes through a bug's mind as he hits your windshield?

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 2:25 PM Flag

    Looks kind of like a dog bone treat.

    Get that order form working on your website and I'll order a dozen for my neighbor's dog.

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 2:20 PM Flag

    Moo,

    Great timing on your ADXS purchase. I'm in that at a way higher price.

    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 2:12 PM Flag

    Matman,

    I'm planning to hold through the successful testing of liver tissue patches. By then there may also be cardiac tissue and cartilage in development. I'm giving myself a very long time frame, just so I don't get overly itchy fingers as this business grows.

    As the share price grows it will increase my margin borrowing power, which I use to buy stocks to sell calls on. So, in a sense I will be profiting from Onvo's growth without having to sell the stock.

    12 months ago, when ONVO was in the $5.00 - $7.00 range, I was making $30,000 - $50,000 per month selling calls. I bought and sold calls on NXPI, CRTO, GILD, and many others I don't remember anymore. When the bottom dropped out of everything I had to decide whether to sell calls with strikes way below my cost basis. Then I lost most of my borrowing power when Onvo went below $3.00, and I actually had a hefty margin call. Now, with Onvo above $3.00, I'm just getting back in the game again. Sold $3,000.00 worth of calls last week. This is a wordy way to say I don't plan or need to cash out my Onvo shares anytime soon.

    Best to you,

    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 1:50 PM Flag

    Not me, not out at $100.00. I took the "Out at $1000.00 pledge."

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 8:25 AM Flag

    For example, in one embodiment, a printer cartridge is filled with a suspension of “cardioclusters” as provided herein and a “smart gel”; the, alternating patterns of the smart gel and cells, or cardioclusters, are printed using a standard print nozzle. In alternative embodiment, a NovoGen (San Diego, Calif.) MMX™, or Organovo Holdings, Inc., bioprinters are used for 3D bioprinting. This and equivalent “bio-printers” can be optimized to “print”, or fabricate, skin tissue, heart tissue, and blood vessels, and other basic tissues, all of which are suitable for surgical therapy and transplantation.

    United States Patent Application 20160166617

    Sentiment: Strong Buy

  • From San Diego State University

    A method for: inducing cardiogenesis in the mammalian heart, tissue repair or tissue regeneration, optionally a cardiac or heart tissue repair or heart tissue regeneration, or optionally a cardiac muscle repair or tissue regeneration, a cardiac vasculature repair or tissue regeneration or a cardiac connective tissue repair or tissue regeneration, comprising: (a) providing: a macrocellular structure, a cardiocluster of cells or an artificially configured plurality of cells as set forth in claim 1; and (b) introducing into, onto or approximate to the mammalian heart, or cardiac or heart tissue, or heart muscle, or cardiac vasculature or connective tissue: the macrocellular structure, a cardiocluster of cells or an artificially configured plurality of cells of (a), thereby inducing cardiogenesis in the mammalian heart, or for repairing or regenerating the tissue, or the cardiac tissue, or the cardiac muscle, cardiac vasculature or cardiac connective tissue.

    16. The method of claim 15, wherein heart has an injury or dysfunction and the method is effective to treat the injury or dysfunction.

    17. The method of claim 15, wherein injury or dysfunction: is an ischemic injury or a heart failure, or results from myocardial infarction (MI).

    18. A method for treating or ameliorating a heart injury, an injury subsequent to a myocardial infarction (MI), a congenital or genetic heart defect, or a heart dysfunction, comprising: (a) providing: a macrocellular structure, a cardiocluster of cells or an artificially configured plurality of cells as set forth in claim 1; and (b) introducing into, onto or approximate to a mammalian heart, or administering to or applying to an individual in need thereof, the macrocellular structure, a cardiocluster of cells or an artificially configured plurality of cells of (a), thereby treating or ameliorating the heart injury, injury subsequent to a myocardial infarction (MI), congenital or genetic heart defect, or

    Sentiment: Strong Buy

  • "Additive manufacturing, also known as 3D printing, is a transformative manufacturing technology that will play a significant role in the critical manufacturing sector. Industrial-grade 3D printers are increasingly used to produce functional parts for important systems. However, due to their reliance on computerization, 3D printers are susceptible to a broad range of attacks. More importantly, compromising a 3D printer is not a goal, but rather a staging point for launching subsequent attacks with the printer. For example, an adversary can compromise a 3D printer in order to manipulate the mechanical properties of manufactured parts. If the manufactured parts are used in jet engines or in other safety-critical systems, they could endanger human life, disrupt critical infrastructure assets and produce significant economic and societal impacts.

    This paper analyzes the ability of an adversary to “weaponize” compromised additive manufacturing equipment in order to cause kinetic, nuclear/biological/chemical or cyber damage. In particular, the paper presents categories (taxonomies) of the elements in an additive manufacturing workflow that can be compromised by successful attacks, the manipulations that the compromised elements can exercise and the weapon-like effects resulting from these manipulations. The relationships between these taxonomies are discussed. Finally, the weaponization capabilities of 3D printers are characterized."

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 7:49 AM Flag

    3D printing with bioink may produce cartilage patches for worn out joints
    Published on June 28, 2016 at 3:42 AM

    "Strands of cow cartilage substitute for ink in a 3D bioprinting process that may one day create cartilage patches for worn out joints, according to a team of engineers. "Our goal is to create tissue that can be used to replace large amounts of worn out tissue or design patches," said Ibrahim T. Ozbolat, associate professor of engineering science and mechanics. "Those who have osteoarthritis in their joints suffer a lot. We need a new alternative treatment for this."

    Cartilage is a good tissue to target for scale-up bioprinting because it is made up of only one cell type and has no blood vessels within the tissue. It is also a tissue that cannot repair itself. Once cartilage is damaged, it remains damaged.

    Previous attempts at growing cartilage began with cells embedded in a hydrogel -- a substance composed of polymer chains and about 90 percent water -- that is used as a scaffold to grow the tissue.

    "Hydrogels don't allow cells to grow as normal," said Ozbolat, who is also a member of the Penn State Huck Institutes of the Life Sciences. "The hydrogel confines the cells and doesn't allow them to communicate as they do in native tissues."

    This leads to tissues that do not have sufficient mechanical integrity. Degradation of the hydrogel also can produce toxic compounds that are detrimental to cell growth.

    Ozbolat and his research team developed a method to produce larger scale tissues without using a scaffold. They create a tiny -- from 3 to 5 one hundredths of an inch in diameter -- tube made of alginate, an algae extract. They inject cartilage cells into the tube and allow them to grow for about a week and adhere to each other. Because cells do not stick to alginate, they can remove the tube and are left with a strand of cartilage. The researchers reported their results in the current issue of Scientific Reports.

    Related Stories
    Long-term opioid th

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 7:28 AM Flag

    Pat,

    I just ran across this article: THIS JOINT IS JUMPING – RESEARCHERS 3D BIOPRINT HUMAN CARTILAGE

    There is a reference to Organovo:

    Patients suffering with arthritis or knee injuries are often plagued by a lack of cartilage. That means bones begin to grind against bones, and that means extreme pain and constant discomfort for patients. Using D'Lima's bioprinting method, cartilage can be applied directly into the knee joint to provide a custom fit impossible to achieve by cutting pre-made cartilage to the particular patient.

    And one day, D'Lima says he's confident that the process will involve printing the cartilage material directly onto a patient on the operating table.

    "We wouldn't have to prepare (material) in advance," D'Lima said. "All of this would be done on the day of surgery, on demand."

    "The major hurdle, according to D'Lima, is that as there's currently no printer which can print directly onto a patient. His technique needs some refining. D'Lima says he's working on those tweaks now with biotech firms Invetech and Organovo."

    Perhaps you could get an update on that project.

    Cheers,

    Juggsy

    Sentiment: Strong Buy

  • twojugglers twojugglers Jun 28, 2016 12:07 AM Flag

    Very cool Pat,

    I'm jealous. Have a great visit and be sure to check in with us when you can.

    Juggsy

    Sentiment: Strong Buy

  • Reply to

    sometimes i just wish ONVO

    by dd4554 Jun 25, 2016 10:20 PM
    twojugglers twojugglers Jun 26, 2016 7:16 PM Flag

    Love that target price Moo. I'm setting that for my 1st sell price.

    Sentiment: Strong Buy

DK
13.15+0.50(+3.95%)4:02 PMEDT